Incretin-pathway peptides: what the research literature studies

Incretins are hormones released by the gut in response to a meal. The native hormones — GLP-1, GIP, glucagon and amylin — each act on their own G-protein-coupled receptor, and a large body of published pharmacology research uses synthetic analogues of these hormones as tools to study insulin secretion, gastric emptying, appetite-related signalling and energy metabolism in cell lines and animal models.

GLP-1 receptor agonism is the most studied of the four. The published literature describes GLP-1 receptor activation increasing cAMP signalling in pancreatic beta cells, which is linked in animal models to glucose-dependent insulin release — glucose-dependent meaning the effect is tied to glucose levels already present, a distinction that recurs throughout this literature. Analogues differ in amino acid substitutions and fatty-acid conjugation, which published pharmacokinetic studies link to differences in receptor binding half-life and resistance to DPP-4 degradation, the enzyme that breaks down native GLP-1 within minutes.

Dual and triple agonists — molecules engineered to activate more than one of these receptors at once — are a newer research direction. Published comparative studies report that combining GLP-1 with GIP or glucagon receptor activity produces different signalling profiles in cell assays than single-receptor agonists, which is why these molecules are used as comparators when researchers characterise receptor selectivity and downstream signalling pathways.

Amylin receptor pharmacology is studied separately: amylin is co-secreted with insulin and, in the published literature, is associated in animal models with gastric emptying rate and satiety-related signalling via different CNS pathways than the GLP-1 receptor. Research combining amylin and GLP-1 receptor agonism studies whether the two pathways produce additive or distinct downstream effects in preclinical models.

All of this describes receptor pharmacology and signalling research, not an application or outcome. The compounds in this category are supplied as reference material for in-vitro and animal-model research into these receptor systems, consistent with the published literature — not as a treatment, supplement or weight-management product, and we don't provide dosing or administration guidance for any of them.